20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Free D-aspartate regulates neuronal dendritic morphology, synaptic plasticity, gray matter volume and brain activity in mammals

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          D-aspartate (D-Asp) is an atypical amino acid, which is especially abundant in the developing mammalian brain, and can bind to and activate N-methyl-D-Aspartate receptors (NMDARs). In line with its pharmacological features, we find that mice chronically treated with D-Asp show enhanced NMDAR-mediated miniature excitatory postsynaptic currents and basal cerebral blood volume in fronto-hippocampal areas. In addition, we show that both chronic administration of D-Asp and deletion of the gene coding for the catabolic enzyme D-aspartate oxidase (DDO) trigger plastic modifications of neuronal cytoarchitecture in the prefrontal cortex and CA1 subfield of the hippocampus and promote a cytochalasin D-sensitive form of synaptic plasticity in adult mouse brains. To translate these findings in humans and consistent with the experiments using Ddo gene targeting in animals, we performed a hierarchical stepwise translational genetic approach. Specifically, we investigated the association of variation in the gene coding for DDO with complex human prefrontal phenotypes. We demonstrate that genetic variation predicting reduced expression of DDO in postmortem human prefrontal cortex is mapped on greater prefrontal gray matter and activity during working memory as measured with MRI. In conclusion our results identify novel NMDAR-dependent effects of D-Asp on plasticity and physiology in rodents, which also map to prefrontal phenotypes in humans.

          Related collections

          Most cited references49

          • Record: found
          • Abstract: found
          • Article: not found

          Translational control of long-lasting synaptic plasticity and memory.

          Long-lasting forms of synaptic plasticity and memory are dependent on new protein synthesis. Recent advances obtained from genetic, physiological, pharmacological, and biochemical studies provide strong evidence that translational control plays a key role in regulating long-term changes in neural circuits and thus long-term modifications in behavior. Translational control is important for regulating both general protein synthesis and synthesis of specific proteins in response to neuronal activity. In this review, we summarize and discuss recent progress in the field and highlight the prospects for better understanding of long-lasting changes in synaptic strength, learning, and memory and implications for neurological diseases.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.

            Glutamate is the primary excitatory neurotransmitter in mammalian brain. Disturbances in glutamate-mediated neurotransmission have been increasingly documented in a range of neuropsychiatric disorders including schizophrenia, substance abuse, mood disorders, Alzheimer's disease, and autism-spectrum disorders. Glutamatergic theories of schizophrenia are based on the ability of N-methyl-D-aspartate receptor (NMDAR) antagonists to induce schizophrenia-like symptoms, as well as emergent literature documenting disturbances of NMDAR-related gene expression and metabolic pathways in schizophrenia. Research over the past two decades has highlighted promising new targets for drug development based on potential pre- and postsynaptic, and glial mechanisms leading to NMDAR dysfunction. Reduced NMDAR activity on inhibitory neurons leads to disinhibition of glutamate neurons increasing synaptic activity of glutamate, especially in the prefrontal cortex. Based on this mechanism, normalizing excess glutamate levels by metabotropic glutamate group 2/3 receptor agonists has led to potential identification of the first non-monoaminergic target with comparable efficacy as conventional antipsychotic drugs for treating positive and negative symptoms of schizophrenia. In addition, NMDAR has intrinsic modulatory sites that are active targets for drug development, several of which show promise in preclinical/early clinical trials targeting both symptoms and cognition. To date, most studies have been done with orthosteric agonists and/or antagonists at specific sites. However, allosteric modulators, both positive and negative, may offer superior efficacy with less danger of downregulation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Temporal dynamics and genetic control of transcription in the human prefrontal cortex.

              Previous investigations have combined transcriptional and genetic analyses in human cell lines, but few have applied these techniques to human neural tissue. To gain a global molecular perspective on the role of the human genome in cortical development, function and ageing, we explore the temporal dynamics and genetic control of transcription in human prefrontal cortex in an extensive series of post-mortem brains from fetal development through ageing. We discover a wave of gene expression changes occurring during fetal development which are reversed in early postnatal life. One half-century later in life, this pattern of reversals is mirrored in ageing and in neurodegeneration. Although we identify thousands of robust associations of individual genetic polymorphisms with gene expression, we also demonstrate that there is no association between the total extent of genetic differences between subjects and the global similarity of their transcriptional profiles. Hence, the human genome produces a consistent molecular architecture in the prefrontal cortex, despite millions of genetic differences across individuals and races. To enable further discovery, this entire data set is freely available (from Gene Expression Omnibus: accession GSE30272; and dbGaP: accession phs000417.v1.p1) and can also be interrogated via a biologist-friendly stand-alone application (http://www.libd.org/braincloud).
                Bookmark

                Author and article information

                Journal
                Transl Psychiatry
                Transl Psychiatry
                Translational Psychiatry
                Nature Publishing Group
                2158-3188
                July 2014
                29 July 2014
                1 July 2014
                : 4
                : 7
                : e417
                Affiliations
                [1 ]Laboratory of Behavioural Neuroscience, Ceinge Biotecnologie Avanzate , Naples, Italy
                [2 ]Department of Molecular Medicine and Medical Biotechnology, University of Naples ‘Federico II' , Naples, Italy
                [3 ]Centro Europeo per la Ricerca sul Cervello (CERC)/Fondazione Santa Lucia , Rome, Italy
                [4 ]Department of Physiology and Pharmacology, Sapienza University of Rome , Rome, Italy
                [5 ]Istituto di Ricovero e Cura a Carattere Scientifico ‘Casa Sollievo della Sofferenza' , San Giovanni Rotondo, Italy
                [6 ]Faculty of Motor Sciences, University of Naples ‘Parthenope' , Naples, Italy
                [7 ]Istituto Italiano di Tecnologia, Center for Neuroscience and Cognitive Systems , Rovereto, Italy
                [8 ]Pharmacology of Synaptic Plasticity Unit, European Brain Research Institute (EBRI) , Rome, Italy
                [9 ]Group of Psychiatric Neuroscience, Department of Neuroscience, Basic Sciences and Sense Organs, University of Bari ‘Aldo Moro' , Bari, Italy
                [10 ]Department of Neuroscience, Tor Vergata University Hospital Foundation , Rome, Italy
                [11 ]pRED, Neuroscience DTA, Hoffman-La Roche, Ltd, Basel, Switzerland
                [12 ]Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, Second University of Naples (SUN) , Caserta, Italy
                Author notes
                [* ]Group of Psychiatric Neuroscience, Department of Neuroscience, Basic Sciences and Sense Organs, University of Bari ‘Aldo Moro' , 70121 Bari, Italy. E-mail: alessandro.bertolino@ 123456uniba.it
                [* ]Laboratory of Behavioural Neuroscience, Ceinge Biotecnologie Avanzate , Via G. Salvatore, 486, 80145 Naples, Italy. E-mail: usiello@ 123456ceinge.unina.it
                [13]

                Share co-first authorship.

                [14]

                Share co-last authorship.

                Article
                tp201459
                10.1038/tp.2014.59
                4119226
                25072322
                cb857815-ed0f-4706-872e-0993c8659525
                Copyright © 2014 Macmillan Publishers Limited

                This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/

                History
                : 27 November 2013
                : 25 April 2014
                : 04 June 2014
                Categories
                Original Article

                Clinical Psychology & Psychiatry
                Clinical Psychology & Psychiatry

                Comments

                Comment on this article